Marijuana Victims' Association: Is Marijuana the New Thalidomide
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 4, 2016) - Phocomelia (limb malformation) has been shown in testing(i) of THC marijuana in a similar preclinical model to that which revealed the teratogenicity of thalidomide.
The federal government is aware of serious marijuana harms; it must not be complicit in risking Canadian health, but must mitigate by placing marijuana products under a protective protocol similar to REVAID used for Thalidomide.
As the stewards of the country's human and financial resources, it is critical that government protect the public from potential irreversible harm and itself from litigation. Marijuana harm is not only possible but probable.
A Health Canada document cites 1,000 scientific references that substantiate the risks.
The June 2016 Government public consultation discussion paper fails to inform the public of the risks, specifically to the fetus and reproduction by males.
If thalidomide offered the "high" of pot would it be reasonable to legalizing it for recreational use?
(i)Ref: Reece AS, Hulse GK. Chromothripsis and epigenomics complete causality criteria for cannabis- and addiction-connected carcinogenicity, congenital toxicity and heritable genotoxicity. Mutat Res. 2016;789:15-25.
Contact Information: Marijuana Victims' Association Pamela McColl SAM Canada 1-778 354 3551
Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCEtm (60mg pre-filled syringe) and XBRYKtm (120mg vial), denosumab biosimilars referencing Prolia and Xgeva ? formerly referred...
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented new data for casdatifan, a HIF-2a inhibitor with...
Product: Fried Falafel with Tahini Sauce
Issue: Food - Allergen - Peanut
Distribution: Alberta Newfoundland and Labrador Ontario
See the affected products and product photos for this recall...
Exelixis, Inc. today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell...
For children with high threshold peanut allergy, oral immunotherapy using store-bought and home-measured peanut products provided significantly higher rates of desensitization compared to peanut avoiders, according to new research being presented at...
LifeNet Health proudly announces the launch of OraGen®, the first viable dental bone allograft comprised of cryopreserved corticocancellous bone containing endogenous lineage-committed bone cells combined with demineralized bone matrix. This unique...